Medication info
Alinoksil Tablet 5 mg (Minoxidil)

Alinoksil Tablet 5 mg (Minoxidil)

Prescription medicationTablet
Ingredient · strength
Minoxidil›5mg / 1 tablet
Manufacturer / importer
Aliko Pharmaceutical Co., Ltd.
Appearance
White or almost white round tablet
Packaging
30 tablets/bottle, 90 tablets/bottle
Approval status
Active

MFDS item code 202600459 · Approved 2026.02.19

Summary

Main use
Treatment of symptomatic hypertension, hypertension with target-organ damage, and resistant hypertension
Who uses it
Adults · Children
Adult dosage
1. Adults (12 years and older): The initial dose of minoxidil is 5㎎ orally once daily, and the maintenance dose is 10-40㎎ daily in 1-several divided doses. Up to 100㎎ may be administered daily. 3. Frequency of administration: During treatment with this medicine, the extent of variation in arterial blood pressure over the course of a day is proportional to the amount of blood pressure reduction. If the reduction in diastolic blood pressure is less than 30mmHg, administration once daily is acceptable; if the reduction in diastolic blood pressure is 30mmHg or more, administer in 2 divided doses daily. 4. Dose adjustment: The dose should be carefully determined according to the patient's response. When adjusting the dose, allow an interval of at least 3 days as a general rule, since an adequate response to a dose may take 3 days or more to appear. If more rapid treatment of hypertension is required, the dose may be adjusted every 6 hours while carefully monitoring the patient. 5. Concomitant administration 1) Diuretics: This medicine is administered with a diuretic in patients who depend on renal function to maintain salt and water balance. It has been administered concomitantly with the following diuretics. ① Hydrochlorothiazide (50㎎ per dose, 2 times daily) or another thiazide diuretic (an equivalent effective dose) ② Chlorthalidone (50-100㎎ per dose, once daily) ③ Furosemide (40㎎ per dose, 2 times daily) If excessive salt and water retention causes a weight gain of approximately 1.8㎏ or more, the diuretic should be changed to furosemide; if the patient is already receiving furosemide, the dose should be increased as needed. 2) β-blockers or other sympatholytic agents: During treatment with this medicine, administer a β-blocker in divided doses equivalent to 80-160㎎ of propranolol daily. If β-blockers are contraindicated, methyldopa (250-750㎎ per dose, 2 times daily) may be administered instead. Since methyldopa takes time to exert its effect, administer it at least 24 hours before starting this medicine. Sympatholytic agents may not completely block the increase in heart rate caused by this medicine, but they can generally prevent tachycardia. Patients receiving a β-blocker before starting treatment with this medicine typically have bradycardia; however, the heart rate is expected to increase to normal with administration of this medicine. When this medicine is administered concomitantly with a β-blocker or other sympatholytic agent, their opposing effects on the heart cancel each other out, resulting in little change in heart rate. The dose may be adjusted as appropriate according to age and symptoms.
Children's dosage
Children (12 years and younger): The initial dose is 0.2㎎/㎏ body weight once daily, and it may be increased by 50-100% until blood pressure is optimally controlled. The maintenance dose is 0.25㎎-1.0㎎/㎏ body weight daily. Up to 50㎎ may be administered daily.

Ingredients

Manufacturer
Aliko Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of symptomatic hypertension, hypertension with target-organ damage, and resistant hypertension

  • Hypertension
  • resistant hypertension
View approved original text

This medication is used to treat hypertension that occurs due to sympathetic or specific organ damage. It is also helpful for difficult hypertension patients who have not responded to diuretics and two types of antihypertensive agents. It is used to effectively control blood pressure and reduce cardiovascular risk in these types of hypertension.

Dosage and Administration

Adult dosage

1. Adults (12 years and older): The initial dose of minoxidil is 5㎎ orally once daily, and the maintenance dose is 10-40㎎ daily in 1-several divided doses. Up to 100㎎ may be administered daily. 3. Frequency of administration: During treatment with this medicine, the extent of variation in arterial blood pressure over the course of a day is proportional to the amount of blood pressure reduction. If the reduction in diastolic blood pressure is less than 30mmHg, administration once daily is acceptable; if the reduction in diastolic blood pressure is 30mmHg or more, administer in 2 divided doses daily. 4. Dose adjustment: The dose should be carefully determined according to the patient's response. When adjusting the dose, allow an interval of at least 3 days as a general rule, since an adequate response to a dose may take 3 days or more to appear. If more rapid treatment of hypertension is required, the dose may be adjusted every 6 hours while carefully monitoring the patient. 5. Concomitant administration 1) Diuretics: This medicine is administered with a diuretic in patients who depend on renal function to maintain salt and water balance. It has been administered concomitantly with the following diuretics. ① Hydrochlorothiazide (50㎎ per dose, 2 times daily) or another thiazide diuretic (an equivalent effective dose) ② Chlorthalidone (50-100㎎ per dose, once daily) ③ Furosemide (40㎎ per dose, 2 times daily) If excessive salt and water retention causes a weight gain of approximately 1.8㎏ or more, the diuretic should be changed to furosemide; if the patient is already receiving furosemide, the dose should be increased as needed. 2) β-blockers or other sympatholytic agents: During treatment with this medicine, administer a β-blocker in divided doses equivalent to 80-160㎎ of propranolol daily. If β-blockers are contraindicated, methyldopa (250-750㎎ per dose, 2 times daily) may be administered instead. Since methyldopa takes time to exert its effect, administer it at least 24 hours before starting this medicine. Sympatholytic agents may not completely block the increase in heart rate caused by this medicine, but they can generally prevent tachycardia. Patients receiving a β-blocker before starting treatment with this medicine typically have bradycardia; however, the heart rate is expected to increase to normal with administration of this medicine. When this medicine is administered concomitantly with a β-blocker or other sympatholytic agent, their opposing effects on the heart cancel each other out, resulting in little change in heart rate. The dose may be adjusted as appropriate according to age and symptoms.

Children's dosage

Children (12 years and younger): The initial dose is 0.2㎎/㎏ body weight once daily, and it may be increased by 50-100% until blood pressure is optimally controlled. The maintenance dose is 0.25㎎-1.0㎎/㎏ body weight daily. Up to 50㎎ may be administered daily.

Precautions

This medication should not be used in patients with certain diseases. For example, it may lower blood pressure while promoting catecholamine secretion from tumors in patients with pheochromocytoma, which can be dangerous. It should also be avoided in patients with pulmonary hypertension due to mitral stenosis, acute myocardial infarction, or known hypersensitivity to this medication. Caution should be applied for patients with chronic congestive heart failure, severe renal failure, or angina, and they should be closely monitored by healthcare professionals. Use of this medication can commonly lead to hypertrichosis, which usually starts around the face and scalp and gradually returns to normal after discontinuation. It is essential for children and women to be adequately informed about these potential side effects. Additionally, rashes, vesicles, and severe allergic reactions may occur, so if any abnormal symptoms appear, immediate consultation with healthcare professionals is necessary. Blood tests may show decreased platelet or white blood cell counts, and liver function tests may also indicate abnormalities. Electrocardiogram changes in T-wave are often observed, but in most cases, it returns to normal with ongoing treatment and does not lead to significant heart function problems. Some patients may experience pericardial effusion or fluid accumulation around the heart, and if symptoms arise, a cardiac ultrasound should be performed. If necessary, additional treatment or discontinuing this medication should be considered. Additionally, weight gain, peripheral edema, increased heart rate, changes in renal function, gastrointestinal disturbances, rashes, gynecomastia, headaches, nausea, vomiting, ECG T-wave changes, decreases in hematocrit and blood counts, and elevated ALP may rarely occur, necessitating caution. This medication is typically used in combination with diuretics to prevent fluid retention and worsening heart failure, and regular monitoring of weight and electrolyte status is essential. It can induce reflex tachycardia or angina as a vasodilator, so beta-blockers and similar medications are often used in combination. Patients with renal failure or undergoing dialysis may require dosage adjustments, and those with myocardial infarction should only receive treatment once their condition stabilizes. In the initial stages of treatment, regular urinalysis, kidney function tests, ECG, chest X-rays, and echocardiograms should be conducted to monitor for abnormalities. This medication may interact with other drugs, so caution is necessary when used with guanethidine, antidepressants, antipsychotics, corticosteroids, or NSAIDs. In particular, severe hypotension can occur with concomitant use of guanethidine, so co-administration should be avoided or initiated in a hospital setting. Safety of this medication has not been established during pregnancy, so it should be avoided; likewise, use during breastfeeding is not recommended, or breastfeeding should be discontinued. There is limited experience using it in children or infants, necessitating careful administration. In cases of overdose, significant hypotension may occur, which may be treated with normal saline injection or specific sympathomimetics. However, some sympathomimetics can burden the heart, requiring caution.

Side effects

Hair growth, thickening, increased pigmentation, exudative rash, vesicular lesions, skin and mucous membrane syndrome, thrombocytopenia, leukopenia, decreased hematocrit, decreased hemoglobin, decreased red blood cells, increased ALP, changes in ECG T-wave direction and amplitude, pericardial effusion, ischemia, peripheral vascular edema, increased heart rate, elevated creatinine, elevated BUN, gastrointestinal disturbance, rash, mastalgia, gynecomastia, hemolytic anemia, pulmonary infiltration, increased antinuclear antibodies, headache, intermittent claudication, frequent menstruation, nausea, vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it must be stored in a sealed container. It is recommended to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help maintain the effectiveness and safety of the medication.

Appearance and packaging

Appearance

White or almost white round tablet

Package unit

30 tablets/bottle, 90 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.